Combined immunosuppression with cyclosporine, rapamycin, and mycophenolate mofetil controls rejection with minimal nutritional impact in experimental small intestinal transplantation.
Sigalet
D L
DL
GI Research Group, University of Calgary and Alberta Children's Hospital, Calgary, Alberta, Canada. sigalet@ucalgary.ca
Thorne
P C
PC
Martin
G R
GR
Garola
R E
RE
Yatscoff
R W
RW
D000824:Animal Nutritional Physiological Phenomena; D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D007421:Intestine, Small / Q000637:transplantation*; D008297:Male; D023421:Models, Animal; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D051381:Rats; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000494:pharmacology*; D014184:Transplantation, Homologous / Q000276:immunology*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D020123:Sirolimus